The heart in uremia

Seminars in Nephrology

Volumn 16, Issue 3, 1996, Pages 214-221

  Massry, Shaul G ^a   Smogorzewski, Miroslaw ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATASE (CALCIUM); ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); ADENOSINE TRIPHOSPHATE; CALCITRIOL; CALCIUM CHANNEL BLOCKING AGENT; ERYTHROPOIETIN; FURA 2; GUANINE NUCLEOTIDE BINDING PROTEIN; NORADRENALIN; PARATHYROID HORMONE; PARATHYROID HORMONE RELATED PROTEIN; PARATHYROID HORMONE[1-34]; UREMIC TOXIN;

CALCIUM TRANSPORT; CARDIOMYOPATHY; CHRONIC KIDNEY FAILURE; ECHOCARDIOGRAPHY; HEART LEFT VENTRICLE HYPERTROPHY; HEMODIALYSIS; HUMAN; HYPERPHOSPHATEMIA; ISCHEMIC HEART DISEASE; MYOCARDIAL DISEASE; NONHUMAN; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SECONDARY HYPERPARATHYROIDISM; UREMIA;

CALCIUM; ECHOCARDIOGRAPHY; HEART DISEASES; HUMANS; PARATHYROID HORMONE; RISK FACTORS; UREMIA;

EID: 0029876459     PISSN: 02709295     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (65)

1. US Renal Data Systems: USRDS 1993 Annual Data Report. Bethesda, MD, The National Institute of Health, National Institute of Diabetes and Digestive and Kidney Disease, 1993, pp 49-54
2. Canadian Organ Replacement Register, 1991 Annual Report, Hospital Medical Records Institute, Don Mills, Ontario, Canada, 1993
3. European Dialysis and Transplant Association: Annual Report on Regular Dialysis and Transplantation in Europe, XXII, 1991
4. Greaves SC, Sharpe DN: Cardiovascular disease in patients with end-stage renal failure. Aust NZ J Med 22:153-159, 1992
5. Derow HW: The heart in renal disease. Circulation 10:114-128, 1954
6. Bailey GL, Hampers CL, Merrill JP: Reversible cardiomyopathy in uremia. Trans Am Soc Artif Intern Organs 13:263-272, 1967
7. Pabico RC, Freeman RB: Pericarditis and myocardiopathy, in Massry SG, Seller A (eds): Clinical Aspects of Uremia and Dialysis. Atlanta, GA, Springfield, Thomas, 1976, pp 69-99
8. London GM, DeVernejoul MC, Fabian! F, et al: Association between aluminum accumulation and cardiac hypertrophy in hemodialyses patients. Am J Kidney Dis 13:75-83, 1989
9. Linder A, Charra B, Sherrad DJ, Scribner BH: Accelerated atherogenesis of prolonged maintenance hemodialysis. N Engl Med 290:697-701, 1974
10. Drueke T, LePailleur C, Sigal-Saglier M, et al: Left ventricular function in hemodialyses patients with cardiomegaly. Nephron 28:80-87, 1981
11. Massry SG, Smogorzewski M, Perna AF: Parathyroid hormone and myocardiopathy of chronic renal failure, in Par-frey PS, Hamett JD (eds): Cardiac Dysfunction in Chronic Uremia. Boston, MA, Kluwer Academic, 1992, pp 139-160
12. Parfrey PS: Cardiac and cerebrovascular disease in chronic uremia. Am J Kidney Dis 21:77-80, 1993
13. Rostand SG, Kirk KA, Rutsky EA: Dialysis-associated ischemic heart disease: Insight from coronary angiography. Kidney Int 25:653-659, 1984
14. Roig E, Betriu A, Castaner A, et al: Disabling angina pectoris with normal coronary arteries in patients undergoing long-term hemodialysis. Am J Med 71:431-434, 1981
15. Rostand SG, Kirk KA, Rutsky EA: Relationship of coronary risk factors to hemodialysis-associated ischemic heart disease. Kidney Int 22:304-308, 1982
16. Amann K, Wiest G, Zimmer G, et al: Reduced capillary density in the myocardium of uremic rats - A stereological study. Kidney Int 42:1079-1085, 1992
17. Foley RN, Parfrey PS, Hamett JD, et al: Clinical and echocardiographic disease in patients starting end-stage renal disease therapy. Kidney Int 47:186-192, 1995
18. Cruz IA, Bhatt GR, Cohen HC: Echocardiographic detection of cardiac involvement in patients with chronic renal failure. Arch Intern Med 138:720-724, 1978
19. Lai KN, Ng J, Whitford J, et al: Left ventricular function in uremia: Echocardiographic and radionuclide assessment in patients on maintenance hemodialysis. Clin Nephrol 23:125-133, 1985
20. Parfrey PS, Hamett JD, Griffiths SM, et al: The clinical course of left ventricular hypertrophy in dialysis patients. Nephron 15:114-120, 1990
21. Hamett JD, Foley RN, Kent GM, et al: Congestive heart failure in dialysis patients: Prevalence, incidence, prognosis and risk factors. Kidney Int 47:884-890, 1995
22. London GM, Fabiani F, Marchais SJ, et al: Uremic cardiomyopathy: An inadequate left ventricular hypertrophy. Kidney Int 31:973-980, 1987
23. London GM, Marchais SJ, Guerin AP, Metivier F: Contributive factors to cardiovascular hypertrophy in renal failure. Am J Hypertens 2:261S-265S, 1989
24. London GM, Marchais SJ, Guerin AP, et al: Cardiac hypertrophy and arterial alterations in end-stage renal disease: Hemodynamic factors. Kidney Int 43:S42-S49, 1993 (Suppl 41)
25. Strauer BE: Myocardial oxygen consumption in chronic heart disease. Role of wall stress, hypertrophy and coronary reserve. Am J Cardiol 44:730-740, 1979
26. Harnett JD, Parfrey PS, Griffiths MH, et al: Left ventricular hypertrophy in end-stage renal disease. Nephron 48:107-115, 1988
27. Leschke M, Schoebal F, Strauer BE: Anemia and the heart, in Bauer C, Koch KM, Scigolla P, et al (eds): Erythropoietin. Molecular Physiology and Clinical Applications. New York, NY, Marcel Dekker, 1993, pp 93-106
28. Neff MS, Kim KE, Persoff M, et al: Hemodynamics of uremic anemia. Circulation 43:876-883, 1971
29. Kim EK, Onesti G, Schwanz AB, et al: Hemodynamics of hypertension in chronic end-stage renal disease. Circulation 46:456-464, 1972
30. Silberberg JS, Rahal DP, Patton DR, Sniderman AD: Role of anemia in the pathogenesis of left ventricular hypertrophy in end stage renal disease. Am J Cardiol 64:222-224, 1989
31. Seyle J: The Pleuricausal Cardiopathies. Atlanta, GA, Springfield, Thomas, 1961
32. Lehr D: The role of certain electrolytes and hormones in disseminated myocardial necrosis, in Bejusz E (ed): Electrolyte and Cardiovascular Disease, Vol 1. Basel, Karger, 1900, pp 208
33. Kraikitpanitch S, Linderman RD, Yunice AA, et al: Effect of azotemia on myocardial accumulation of calcium. Miner Electrolyte Metab 1:12-20, 1978
34. Massry SO, Smogorzewski M: Mechanisms through which parathyroid hormone mediates its deleterious effects on organ function in uremia. Semin Nephrol 14:219-231, 1994
35. Smogorzewski M, Zayed M, Zhang Y-B: Parathyroid hormone increases cytosolic calcium concentration in adult rat cardiac myocytes. Am J Physiol 264:H1998-H2006, 1993
36. Zhang Y-B, Smogorzewski M, Ni Z, Massry SG: Altered cytosolic calcium homeostasis in rat cardiac myocytes in CRF. Kidney Int 45:1113-1119, 1994
37. Bogin E, Massry SG, Harary I: Effect of parathyroid hormone on rat heart cells. J Clin Invest 67:1215-1227, 1981
38. Katoh Y, Klein KL, Kaplan RA, et al: Parathyroid hormone has a positive inotropic action in the rat. Endocrinology 109:2252-2253, 1981
39. Lhoste F, Drueke T, Larus S, Bossier JR: Cardiac interaction between parathyroid hormone, β-adrenoceptor, and verapamil in the guinea-pig in vitro. Clin Exp Pharmacol Physiol 7:377-385, 1980
40. Horiuchi N, Holick MF, Potts JT Jr, Rosenblatt M: A parathyroid hormone inhibitor in vivo: Design and biological evaluation of a hormone analog. Science (Washington) 220:1053-1055, 1983
41. Urena P, Kong X-F, Abou-Samara A-B, et al: Parathyroid hormone (PTH)/PTH-related peptide receptor messenger ribonucleic acids are widely distributed in rat tissues. Endocrinology 133:617-623, 1993
42. Tian J, Smogorzewski M, Kedes L, Massry SG: Parathyroid hormone related protein receptors messenger RNA is present in many tissues besides the kidney. Am J Nephrol 13:210-213, 1993
43. Zhang Y-B, Smogorzewski M, Ni Z, Massry SG: Altered cytosolic calcium homeostasis in rat cardiac myocytes. Kidney Int 45:1113-1119, 1994
44. Raine AE, Seymour AML, Roberts AFC, et al: Impairment of cardiac function and energetics in experimental renal failure. J Clin Invest 92:2934-2940, 1993
45. Baczynski R, Massry SG, Kohan R, et al: Effect of parathyroid hormone on myocardial energy metabolism in the rat. Kidney Int 27:718-725, 1985
46. 2+-transport by mammalian mitochondria and its role in hormone action. Am J Physiol 249:E543-E554, 1985
47. Trump BE, Berezsky IK: The role of ion deregulation in toxic cell injury. Adv Modern Env Toxicol 14:27-50, 1987
48. Carafoli E: Calcium pumps of the plasma membrane. Physiol Rev 71:129-153, 1991
49. Langer GA: Calcium and the heart: Exchange at the tissue, cell and organeile levels. FASEB J 6:893-902, 1992
50. 2+ exchanger, in Langer GA (ed): Calcium and the Heart, New York, NY, Raven Press, 1990, pp 85-108
51. Deitmer JW, Ellis DA: Interactions between the regulation of the intracellular pH and sodium activity of sheep cardiac Purkinje fibers. J Physiol (London) 307:471-488, 1980
52. El-Belbessi S, Brautbar N, Anderson K, et al: Effect of chroic renal failure on heart: Role of secondary hyperparathyroidtsm. Am J Nephrol 6:269-275, 1986
53. Smogorzewski M, Perna AF, Borum PR, Massry SG: Fatty acid oxidation in the myocardium: Effects of parathyroid hormone and CRF. Kidney Int 34:797-803, 1988
54. Amann K, Ritz E, Wiest G, et al: Role of parthyroid for the activation of cardiac fibroblasts in uremia. J Am Soc Nephrol 4:1814-1819, 1994
55. i. Kidney Int 47:1182-1186, 1992
56. Perna AF, Smogorzewski M, Massry SG: Effect of verapamil on the abnormalities in fatty acid oxidation of myocardium. Kidney Int 36:453-457, 1989
57. Drueke T, Fleury J, Toure Y, et al: Effect of parathyroidectomy on left ventricular function in hemodialysis patients. Lancet 1:112-114, 1980
58. McGonigle RJS, Fowler MB, Timmis AB, et al: Ure mic cardiomyopathy: Potential role of vitamin D and parathyroid hromone. Nephron 36:94-100, 1984
59. Eren Z, Cifta H, Kiper H, et al: Left ventricular functions and morphology in patients on maintenance haemodialysis: Effect of slow release verapamil. Proceedings of the Turkish Society of Nephrology, Adana, Turkey, 26-27, 1988
60. Symons C, Fortune F, Greenbaum RA, Dandona P: Cardiac hypertrophy, hypertrophic cardiomyopathy and hyperparathyroidism - An association. Br Heart J 54:539-542, 1985
61. Bauwens FR, Duprez DA, DeBuyzere ML, et al: Influence of the arterial blood pressure and nonhemodynamic factors on left ventricular hypertrophy in moderate essential hypertension. Am J Cardiol 68:925-929, 1991
62. Sikole A, Polenakovic M, Spirovska V, et al: Analysis of heart morphology and function following erythropoietin treatment of anemic dialysis patients. Artif Organs 17:977-984, 1993
63. London GM, Zins B, Pannier BE, et al: Vascular changes in hemodialysis patients in response to recombinant human erythropoietin. Kidney Int 36:878-882, 1989
64. Eshbach J, Aquiling T, Haley T, et al: The long-term effects of recombinant human erythropoietin on the cardiovascular system. Clin Nephrol 38:S98-S103, 1992 (Suppl 1)
65. Fellner SK, Lang RM, Neuman A, et al: Cardiovascular consequences of correction of the anemia of renal failure with erythropoietin. Kidney Int 44:1309-1315, 1993